Logo image of CGC

CANOPY GROWTH CORP (CGC) Stock Fundamental Analysis

USA - NASDAQ:CGC - CA1380357048 - Common Stock

1.37 USD
-0.01 (-0.72%)
Last: 9/19/2025, 5:20:15 PM
1.3701 USD
+0 (+0.01%)
After Hours: 9/19/2025, 5:20:15 PM
Fundamental Rating

2

CGC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. CGC has a bad profitability rating. Also its financial health evaluation is rather negative. CGC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CGC has reported negative net income.
In the past year CGC has reported a negative cash flow from operations.
In the past 5 years CGC always reported negative net income.
In the past 5 years CGC always reported negative operating cash flow.
CGC Yearly Net Income VS EBIT VS OCF VS FCFCGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1B -2B -3B

1.2 Ratios

Looking at the Return On Assets, with a value of -56.65%, CGC is doing worse than 63.78% of the companies in the same industry.
CGC's Return On Equity of -104.81% is on the low side compared to the rest of the industry. CGC is outperformed by 60.71% of its industry peers.
Industry RankSector Rank
ROA -56.65%
ROE -104.81%
ROIC N/A
ROA(3y)-83.37%
ROA(5y)-56.25%
ROE(3y)-219.63%
ROE(5y)-143.17%
ROIC(3y)N/A
ROIC(5y)N/A
CGC Yearly ROA, ROE, ROICCGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

CGC has a Gross Margin of 27.83%. This is comparable to the rest of the industry: CGC outperforms 54.59% of its industry peers.
The Profit Margin and Operating Margin are not available for CGC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGC Yearly Profit, Operating, Gross MarginsCGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGC has been increased compared to 1 year ago.
The number of shares outstanding for CGC has been reduced compared to 5 years ago.
The debt/assets ratio for CGC has been reduced compared to a year ago.
CGC Yearly Shares OutstandingCGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
CGC Yearly Total Debt VS Total AssetsCGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

CGC has an Altman-Z score of -11.89. This is a bad value and indicates that CGC is not financially healthy and even has some risk of bankruptcy.
CGC's Altman-Z score of -11.89 is on the low side compared to the rest of the industry. CGC is outperformed by 72.96% of its industry peers.
A Debt/Equity ratio of 0.63 indicates that CGC is somewhat dependend on debt financing.
The Debt to Equity ratio of CGC (0.63) is worse than 65.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Altman-Z -11.89
ROIC/WACCN/A
WACC12.59%
CGC Yearly LT Debt VS Equity VS FCFCGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

CGC has a Current Ratio of 3.07. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.
CGC has a Current ratio of 3.07. This is comparable to the rest of the industry: CGC outperforms 57.65% of its industry peers.
CGC has a Quick Ratio of 2.12. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.
CGC has a Quick ratio (2.12) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.07
Quick Ratio 2.12
CGC Yearly Current Assets VS Current LiabilitesCGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

3

3. Growth

3.1 Past

CGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.18%, which is quite impressive.
CGC shows a decrease in Revenue. In the last year, the revenue decreased by -4.25%.
Measured over the past years, CGC shows a decrease in Revenue. The Revenue has been decreasing by -7.57% on average per year.
EPS 1Y (TTM)55.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
Revenue 1Y (TTM)-4.25%
Revenue growth 3Y-19.22%
Revenue growth 5Y-7.57%
Sales Q2Q%8.94%

3.2 Future

The Earnings Per Share is expected to grow by 15.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.90% on average over the next years.
EPS Next Y87.72%
EPS Next 2Y39.4%
EPS Next 3Y25.31%
EPS Next 5Y15.29%
Revenue Next Year8.32%
Revenue Next 2Y5.98%
Revenue Next 3Y7.04%
Revenue Next 5Y6.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CGC Yearly Revenue VS EstimatesCGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CGC Yearly EPS VS EstimatesCGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGC Price Earnings VS Forward Price EarningsCGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGC Per share dataCGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as CGC's earnings are expected to grow with 25.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.4%
EPS Next 3Y25.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANOPY GROWTH CORP

NASDAQ:CGC (9/19/2025, 5:20:15 PM)

After market: 1.3701 +0 (+0.01%)

1.37

-0.01 (-0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners8.19%
Inst Owner Change11.26%
Ins Owners0.94%
Ins Owner Change51.05%
Market Cap364.57M
Analysts46.15
Price Target2.73 (99.27%)
Short Float %8.81%
Short Ratio1.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-99.21%
Min EPS beat(2)-206.63%
Max EPS beat(2)8.22%
EPS beat(4)1
Avg EPS beat(4)-132.67%
Min EPS beat(4)-231.12%
Max EPS beat(4)8.22%
EPS beat(8)1
Avg EPS beat(8)-186.16%
EPS beat(12)2
Avg EPS beat(12)-180.17%
EPS beat(16)4
Avg EPS beat(16)-164.19%
Revenue beat(2)2
Avg Revenue beat(2)8.61%
Min Revenue beat(2)7.65%
Max Revenue beat(2)9.57%
Revenue beat(4)3
Avg Revenue beat(4)5.74%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)9.57%
Revenue beat(8)5
Avg Revenue beat(8)3.48%
Revenue beat(12)7
Avg Revenue beat(12)1.93%
Revenue beat(16)8
Avg Revenue beat(16)-0.87%
PT rev (1m)11.1%
PT rev (3m)2.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.36%
EPS NY rev (1m)-17%
EPS NY rev (3m)-17%
Revenue NQ rev (1m)3.78%
Revenue NQ rev (3m)2.72%
Revenue NY rev (1m)10.53%
Revenue NY rev (3m)1.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.83
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.75
BVpS1.33
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.65%
ROE -104.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.83%
FCFM N/A
ROA(3y)-83.37%
ROA(5y)-56.25%
ROE(3y)-219.63%
ROE(5y)-143.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.16%
Cap/Sales 3.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.07
Quick Ratio 2.12
Altman-Z -11.89
F-Score5
WACC12.59%
ROIC/WACCN/A
Cap/Depr(3y)15.39%
Cap/Depr(5y)45.04%
Cap/Sales(3y)2.72%
Cap/Sales(5y)9.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
EPS Next Y87.72%
EPS Next 2Y39.4%
EPS Next 3Y25.31%
EPS Next 5Y15.29%
Revenue 1Y (TTM)-4.25%
Revenue growth 3Y-19.22%
Revenue growth 5Y-7.57%
Sales Q2Q%8.94%
Revenue Next Year8.32%
Revenue Next 2Y5.98%
Revenue Next 3Y7.04%
Revenue Next 5Y6.9%
EBIT growth 1Y47.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.26%
EBIT Next 3Y32.9%
EBIT Next 5Y20.92%
FCF growth 1Y76.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.03%
OCF growth 3YN/A
OCF growth 5YN/A